Although the status of EGFR and K-ras mutations has been proposed to guide patient selection for anti-EGFR TKI therapy, the majority of EGFR and K-ras mutations are evaluated only in primary tumors because tumor tissue from the metastatic site is not always available. The gene discussed is EGFR; the disease is neoplasm.